Can Pretreatment MRI be Used to Predict Intra-arterial Chemotherapy Response in Retinoblastoma?

NCT03267459 | Recruiting

• 1 other identifier: ALR_2017_2
• Study Type: observational
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

Retinoblastoma is the most frequent intraocular tumor in children and represents 6% of all pediatric cancers before the age of 5 years-old. The outcome is now excellent with 95 to 97% of 5-years survival rate. Conservative treatments are being more and more used, and intra arterial chemotherapy is one of the adjuvant treatments proposed to the children. The treatment is efficient in most cases, but a small proportion of children will have an early progression after treatment. MRI is used for the diagnosis of retinoblastoma. We aim to find prognostic factors using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) for early identification of children response to intra arterial chemotherapy.

Conditions

Retinoblastoma

Outcome Measures

Primary Outcomes (1)

• response to chemotherapy

  Persistence of ocular scarring (= favorable outcome)18 months after the end of the treatment by intra-arterial chemotherapy.

  18 months

Interventions

Dynamic contrast-enhanced MRI DEVICE

Dynamic contrast-enhanced perfusion sequences added to MRI examination performed at the beginning of intra arterial chemotherapy.

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

patient with retinoblastoma, undergoing intra arterial chemotherapy

You may qualify if:

• grade B to D retinoblastoma
• prescription of intra arterial chemotherapy

You may not qualify if:

• none

Sponsors & Collaborators

• Fondation Ophtalmologique Adolphe de Rothschild: lead

Study Sites (1)

Fondation A De Rothschild

Paris, 75019, France

RECRUITING

MeSH Terms

Conditions

Retinoblastoma

Interventions

Dynamic Contrast Enhanced Magnetic Resonance Imaging

Condition Hierarchy (Ancestors)

Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue; Retinal Neoplasms; Eye Neoplasms; Neoplasms by Site; Eye Diseases, Hereditary; Eye Diseases; Retinal Diseases

Intervention Hierarchy (Ancestors)

Magnetic Resonance Imaging; Tomography; Diagnostic Imaging; Diagnostic Techniques and Procedures; Diagnosis

Study Officials

• Augustin Lecler, MD

  Fondation OPH A de Rothschild

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Laurence Salomon, MD PhD

CONTACT

0148036431; lsalomon@for.paris

Augustin Lecler, MD

CONTACT

alecler@for.paris

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: NETWORK
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 28, 2017
• First Posted: August 30, 2017
• Study Start: January 11, 2018
• Primary Completion (Estimated): January 1, 2028
• Study Completion (Estimated): July 1, 2030
• Last Updated: January 5, 2026

Record last verified: 2025-12

Locations

FR (1)